Francoise Mazingue
Overview
Explore the profile of Francoise Mazingue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
762
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahlaoui N, Fouyssac F, Mazingue F, Mallebranche C, Barthez-Toullec M, Denti L, et al.
Front Pediatr
. 2023 Oct;
11:1260296.
PMID: 37849499
Introduction: This study presents the results of a real-life, multicenter, prospective, post-approval safety evaluation of Clairyg® 50 mg/mL, a 5% intravenous immunoglobulin (IVIg) liquid, in 59 children (aged < 12...
2.
Barbati M, Kicinski M, Suciu S, Mazingue F, Vandecruys E, Plat G, et al.
Eur J Cancer Care (Engl)
. 2022 Oct;
31(6):e13755.
PMID: 36284405
Objective: The objective of this study is to evaluate the socio-economic outcomes of survivors of childhood acute lymphoblastic leukaemia (ALL). Methods: Childhood ALL adult survivors, enrolled in EORTC trials between...
3.
Fremond M, Hadchouel A, Berteloot L, Melki I, Bresson V, Barnabei L, et al.
J Allergy Clin Immunol Pract
. 2020 Nov;
9(2):803-818.e11.
PMID: 33217613
Background: Gain-of-function mutations in STING1 underlie a type I interferonopathy termed SAVI (STING-associated vasculopathy with onset in infancy). This severe disease is variably characterized by early-onset systemic inflammation, skin vasculopathy,...
4.
Piette C, Suciu S, Bertrand Y, Uyttebroeck A, Vandecruys E, Plat G, et al.
Br J Haematol
. 2019 Dec;
189(2):351-362.
PMID: 31837008
We investigated the long-term outcome, the incidence of second neoplasms (SN) and the rate of late adverse effects (LAE) in children with central nervous system (CNS) negative medium/high-risk de novo...
5.
Coignard-Biehler H, Mahlaoui N, Pilmis B, Barlogis V, Brosselin P, de Vergnes N, et al.
J Clin Immunol
. 2019 Aug;
39(7):702-712.
PMID: 31401750
Purpose: Patients with primary immunodeficiency (PID) are at risk of serious complications. However, data on the incidence and causes of emergency hospital admissions are scarce. The primary objective of the...
6.
Delebarre M, Dessein R, Lagree M, Mazingue F, Sudour-Bonnange H, Martinot A, et al.
J Infect
. 2019 Jun;
79(2):95-100.
PMID: 31228471
Objective: To describe and analyze the differences between infections in children with febrile neutropenia (FN) treated for solid tumor or blood cancer. Methods: A prospective study included all episodes of...
7.
Hofmans M, Suciu S, Ferster A, Van Vlierberghe P, Mazingue F, Sirvent N, et al.
Br J Haematol
. 2019 May;
186(5):741-753.
PMID: 31124581
Outcomes in childhood T-cell acute lymphoblastic leukaemia (T-ALL) are steadily improving due to intensive therapy. Between 1989 and 2008, 599 children with newly diagnosed T-ALL were enrolled in two successive...
8.
Cornu M, Bruno B, Loridant S, Navarin P, Francois N, Lanternier F, et al.
BMC Pharmacol Toxicol
. 2018 Dec;
19(1):81.
PMID: 30522521
Background: The use of isavuconazole is approved for the management of invasive aspergillosis and mucormycosis, only in adults, as no paediatric pharmacology studies have been reported to date. Very few...
9.
Heritier S, Barkaoui M, Miron J, Thomas C, Moshous D, Lambilliotte A, et al.
Br J Haematol
. 2018 Nov;
183(4):608-617.
PMID: 30421536
Neurodegenerative (ND) complications in Langerhans cell histiocytosis (LCH) are a late-onset but dramatic sequelae for which incidence and risk factors are not well defined. Based on a national prospective registry...
10.
Sokol H, Mahlaoui N, Aguilar C, Bach P, Join-Lambert O, Garraffo A, et al.
J Allergy Clin Immunol
. 2018 Oct;
143(2):775-778.e6.
PMID: 30312711
No abstract available.